NCT01843400View on ClinicalTrials.gov

Regorafenib Post-marketing Surveillance

CompletedOBSERVATIONAL

Enrollment

1,301

Participants

Timeline

Start Date

April 22, 2013

Primary Completion Date

September 12, 2016

Study Completion Date

November 14, 2016

Conditions

Colorectal Neoplasms

Interventions

DRUG

Regorafenib (Stivarga, BAY73-4506)

Patients treated with Regorafenib under practical manner for colorectal cancer.

Trial Locations (1)

Unknown

Multiple Locations

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY